Novartis Bid to Block Rival Entresto Rejected by Appeals Court

Novartis AG failed to establish it would likely succeed in a patent-infringement suit over rival copies of its heart failure drug Entresto, the Federal Circuit affirmed Wednesday.

The US Court of Appeals for the Federal Circuit affirmed a lower court’s rejection to Novartis’ motion for a preliminary injunction to enjoin MSN Pharmaceuticals Inc. from launching its generic version of Entresto.

Novartis alleged MSN’s generic would infringe on its US Patent No. 11,096,918, or the ‘918 patent. The patent, which expires in November 2026, covers the amorphous solid form of the drug’s active compound, a combination of sacubitril and valsartan, ...